120 related articles for article (PubMed ID: 19700222)
1. c-Abl tyrosine kinase modulates tau pathology and Cdk5 phosphorylation in AD transgenic mice.
Cancino GI; Perez de Arce K; Castro PU; Toledo EM; von Bernhardi R; Alvarez AR
Neurobiol Aging; 2011 Jul; 32(7):1249-61. PubMed ID: 19700222
[TBL] [Abstract][Full Text] [Related]
2. STI571 prevents apoptosis, tau phosphorylation and behavioural impairments induced by Alzheimer's beta-amyloid deposits.
Cancino GI; Toledo EM; Leal NR; Hernandez DE; Yévenes LF; Inestrosa NC; Alvarez AR
Brain; 2008 Sep; 131(Pt 9):2425-42. PubMed ID: 18559370
[TBL] [Abstract][Full Text] [Related]
3. Phosphorylated tau in neuritic plaques of APP(sw)/Tau (vlw) transgenic mice and Alzheimer disease.
Pérez M; Morán MA; Ferrer I; Avila J; Gómez-Ramos P
Acta Neuropathol; 2008 Oct; 116(4):409-18. PubMed ID: 18679696
[TBL] [Abstract][Full Text] [Related]
4. Alpha1-antichymotrypsin, an inflammatory protein overexpressed in Alzheimer's disease brain, induces tau phosphorylation in neurons.
Padmanabhan J; Levy M; Dickson DW; Potter H
Brain; 2006 Nov; 129(Pt 11):3020-34. PubMed ID: 16987932
[TBL] [Abstract][Full Text] [Related]
5. Memantine protects rat cortical cultured neurons against beta-amyloid-induced toxicity by attenuating tau phosphorylation.
Song MS; Rauw G; Baker GB; Kar S
Eur J Neurosci; 2008 Nov; 28(10):1989-2002. PubMed ID: 19046381
[TBL] [Abstract][Full Text] [Related]
6. Expression of stress-activated kinases c-Jun N-terminal kinase (SAPK/JNK-P) and p38 kinase (p38-P), and tau hyperphosphorylation in neurites surrounding betaA plaques in APP Tg2576 mice.
Puig B; Gómez-Isla T; Ribé E; Cuadrado M; Torrejón-Escribano B; Dalfó E; Ferrer I
Neuropathol Appl Neurobiol; 2004 Oct; 30(5):491-502. PubMed ID: 15488025
[TBL] [Abstract][Full Text] [Related]
7. Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic models.
Ferrer I; Barrachina M; Puig B; Martínez de Lagrán M; Martí E; Avila J; Dierssen M
Neurobiol Dis; 2005 Nov; 20(2):392-400. PubMed ID: 16242644
[TBL] [Abstract][Full Text] [Related]
8. Parallel increase in p70 kinase activation and tau phosphorylation (S262) with Abeta overproduction.
Zhou XW; Tanila H; Pei JJ
FEBS Lett; 2008 Jan; 582(2):159-64. PubMed ID: 18068129
[TBL] [Abstract][Full Text] [Related]
9. Phosphorylation of Tau at S422 is enhanced by Abeta in TauPS2APP triple transgenic mice.
Grueninger F; Bohrmann B; Czech C; Ballard TM; Frey JR; Weidensteiner C; von Kienlin M; Ozmen L
Neurobiol Dis; 2010 Feb; 37(2):294-306. PubMed ID: 19781645
[TBL] [Abstract][Full Text] [Related]
10. Genetically augmenting tau levels does not modulate the onset or progression of Abeta pathology in transgenic mice.
Oddo S; Caccamo A; Cheng D; Jouleh B; Torp R; LaFerla FM
J Neurochem; 2007 Aug; 102(4):1053-63. PubMed ID: 17472708
[TBL] [Abstract][Full Text] [Related]
11. c-Abl modulates AICD dependent cellular responses: transcriptional induction and apoptosis.
Vázquez MC; Vargas LM; Inestrosa NC; Alvarez AR
J Cell Physiol; 2009 Jul; 220(1):136-43. PubMed ID: 19306298
[TBL] [Abstract][Full Text] [Related]
12. Tau hyperphosphorylation correlates with reduced methylation of protein phosphatase 2A.
Zhou XW; Gustafsson JA; Tanila H; Bjorkdahl C; Liu R; Winblad B; Pei JJ
Neurobiol Dis; 2008 Sep; 31(3):386-94. PubMed ID: 18586097
[TBL] [Abstract][Full Text] [Related]
13. AbetaPP induces cdk5-dependent tau hyperphosphorylation in transgenic mice Tg2576.
Otth C; Concha II; Arendt T; Stieler J; Schliebs R; González-Billault C; Maccioni RB
J Alzheimers Dis; 2002 Oct; 4(5):417-30. PubMed ID: 12446973
[TBL] [Abstract][Full Text] [Related]
14. Activation of the neuronal c-Abl tyrosine kinase by amyloid-beta-peptide and reactive oxygen species.
Alvarez AR; Sandoval PC; Leal NR; Castro PU; Kosik KS
Neurobiol Dis; 2004 Nov; 17(2):326-36. PubMed ID: 15474370
[TBL] [Abstract][Full Text] [Related]
15. Reduction of Blood Amyloid-β Oligomers in Alzheimer's Disease Transgenic Mice by c-Abl Kinase Inhibition.
Estrada LD; Chamorro D; Yañez MJ; Gonzalez M; Leal N; von Bernhardi R; Dulcey AE; Marugan J; Ferrer M; Soto C; Zanlungo S; Inestrosa NC; Alvarez AR
J Alzheimers Dis; 2016 Oct; 54(3):1193-1205. PubMed ID: 27567806
[TBL] [Abstract][Full Text] [Related]
16. Active glycogen synthase kinase-3 and tau pathology-related tyrosine phosphorylation in pR5 human tau transgenic mice.
Köhler C; Dinekov M; Götz J
Neurobiol Aging; 2013 May; 34(5):1369-79. PubMed ID: 23294633
[TBL] [Abstract][Full Text] [Related]
17. Altered subcellular distribution of c-Abl in Alzheimer's disease.
Jing Z; Caltagarone J; Bowser R
J Alzheimers Dis; 2009; 17(2):409-22. PubMed ID: 19363261
[TBL] [Abstract][Full Text] [Related]
18. Cdk5 as a drug target for the treatment of Alzheimer's disease.
Lau LF; Seymour PA; Sanner MA; Schachter JB
J Mol Neurosci; 2002 Dec; 19(3):267-73. PubMed ID: 12540052
[TBL] [Abstract][Full Text] [Related]
19. Cables links Cdk5 and c-Abl and facilitates Cdk5 tyrosine phosphorylation, kinase upregulation, and neurite outgrowth.
Zukerberg LR; Patrick GN; Nikolic M; Humbert S; Wu CL; Lanier LM; Gertler FB; Vidal M; Van Etten RA; Tsai LH
Neuron; 2000 Jun; 26(3):633-46. PubMed ID: 10896159
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of tau phosphorylating protein kinase cdk5 prevents beta-amyloid-induced neuronal death.
Alvarez A; Toro R; Cáceres A; Maccioni RB
FEBS Lett; 1999 Oct; 459(3):421-6. PubMed ID: 10526177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
